Expression of Sialyl-Tn Sugar Antigen in Bladder Cancer Cells Affects Response to (BCG) and to Oxidative Damage

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Sep 15

PMID 28903359

Citations 11

Authors

Paulo F Severino

Mariana Silva

Mylene Carrascal

Nadia Malagolini

Mariella Chiricolo

Giulia Venturi

Annalisa Astolfi

Mariangela Catera

Paula A Videira

Fabio DallOlio

Affiliations

Soon will be listed here.

Abstract

The sialyl-Tn (sTn) antigen is an -linked carbohydrate chain aberrantly expressed in bladder cancer (BC), whose biosynthesis is mainly controlled by the sialyltransferase ST6GALNAC1. Treatment with (BCG) is the most effective adjuvant immunotherapy for superficial BC but one third of the patients fail to respond. A poorly understood correlation between the expression of sTn and BC patient's response to BCG was previously observed. By analyzing tumor tissues, we showed that patients with high ST6GALNAC1 and IL-6 mRNA expression were BCG responders. To investigate the role of sTn in BC cell biology and BCG response, we established the cell lines MCR and MCR by retroviral transduction of the BC cell line MCR with the cDNA or with an empty vector, respectively. Compared with MCR, BCG-stimulated MCR secreted higher levels of IL-6 and IL-8 and their secretome induced a stronger IL-6, IL-1β, and TNFα secretion by macrophages, suggesting the induction of a stronger inflammatory response. Transcriptomic analysis of MCR and MCR revealed that /sTn expression modulates hundreds of genes towards a putative more malignant phenotype and down-regulates several genes maintaining genomic stability. Consistently, MCR cells displayed higher HO sensitivity. In MCR,, BCG challenge induced an increased expression of several regulatory non coding RNA genes. These results indicate that the expression of /sTn improves the response to BCG therapy by inducing a stronger macrophage response and alters gene expression towards malignancy and genomic instability, increasing the sensitivity of BC cells to the oxidizing agents released by BCG.

Citing Articles

Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer.

Ferreira E, Ferreira D, Relvas-Santos M, Freitas R, Soares J, Azevedo R Int J Mol Sci. 2024; 25(6).

PMID: 38542435 PMC: 10971045. DOI: 10.3390/ijms25063462.

Targeting the macrophage immunocheckpoint: a novel insight into solid tumor immunotherapy.

Zhou B, Yang Y, Kang Y, Hou J, Yang Y Cell Commun Signal. 2024; 22(1):66.

PMID: 38273373 PMC: 10809660. DOI: 10.1186/s12964-023-01384-x.

Altered Glycosylation in Progression and Management of Bladder Cancer.

Wilczak M, Surman M, PRZYBYlO M Molecules. 2023; 28(8).

PMID: 37110670 PMC: 10146225. DOI: 10.3390/molecules28083436.

State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer.

Kong C, Zhang S, Lei Q, Wu S Biosensors (Basel). 2022; 12(10).

PMID: 36290934 PMC: 9599190. DOI: 10.3390/bios12100796.

Contrasting Metabolic Insufficiency in Aging and Dementia.

Turner D Aging Dis. 2021; 12(4):1081-1096.

PMID: 34221551 PMC: 8219502. DOI: 10.14336/AD.2021.0104.

References

Carretero R, Cabrera T, Gil H, Saenz-Lopez P, Maleno I, Aptsiauri N . Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells. Int J Cancer. 2010; 129(4):839-46. DOI: 10.1002/ijc.25733. View

Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, Raemaekers J . A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn. 2001; 3(2):55-61. PMC: 1910699. DOI: 10.1016/S1525-1578(10)60652-6. View

Munkley J, Oltean S, Vodak D, Wilson B, Livermore K, Zhou Y . The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget. 2015; 6(33):34358-74. PMC: 4741458. DOI: 10.18632/oncotarget.6024. View

Carrascal M, Severino P, Cabral M, Silva M, Ferreira J, Calais F . Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells. Mol Oncol. 2014; 8(3):753-65. PMC: 5528624. DOI: 10.1016/j.molonc.2014.02.008. View

Costa C, Pereira S, Lima L, Peixoto A, Fernandes E, Neves D . Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics. PLoS One. 2015; 10(11):e0141253. PMC: 4646664. DOI: 10.1371/journal.pone.0141253. View

Videira P, Correia M, Malagolini N, Crespo H, Ligeiro D, Calais F . ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer. 2009; 9:357. PMC: 2763879. DOI: 10.1186/1471-2407-9-357. View

Loureiro L, Carrascal M, Barbas A, Ramalho J, Novo C, Delannoy P . Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. Biomolecules. 2015; 5(3):1783-809. PMC: 4598775. DOI: 10.3390/biom5031783. View

Kiss-Laszlo Z, Henry Y, Bachellerie J, Caizergues-Ferrer M, Kiss T . Site-specific ribose methylation of preribosomal RNA: a novel function for small nucleolar RNAs. Cell. 1996; 85(7):1077-88. DOI: 10.1016/s0092-8674(00)81308-2. View

Ferreira J, Videira P, Lima L, Pereira S, Silva M, Carrascal M . Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours. Mol Oncol. 2013; 7(3):719-31. PMC: 5528473. DOI: 10.1016/j.molonc.2013.03.001. View

10.

Beatson R, Maurstad G, Picco G, Arulappu A, Coleman J, Wandell H . The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL. PLoS One. 2015; 10(5):e0125994. PMC: 4423978. DOI: 10.1371/journal.pone.0125994. View

11.

DallOlio F, Malagolini N, Trinchera M, Chiricolo M . Mechanisms of cancer-associated glycosylation changes. Front Biosci (Landmark Ed). 2011; 17(2):670-99. DOI: 10.2741/3951. View

12.

Tamura F, Sato Y, Hirakawa M, Yoshida M, Ono M, Osuga T . RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells. Gastric Cancer. 2014; 19(1):85-97. DOI: 10.1007/s10120-014-0454-z. View

13.

Ohyama C . Glycosylation in bladder cancer. Int J Clin Oncol. 2008; 13(4):308-13. DOI: 10.1007/s10147-008-0809-8. View

14.

Marcos N, Pinho S, Grandela C, Cruz A, Samyn-Petit B, Harduin-Lepers A . Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res. 2004; 64(19):7050-7. DOI: 10.1158/0008-5472.CAN-04-1921. View

15.

Julien S, Krzewinski-Recchi M, Harduin-Lepers A, Gouyer V, Huet G, Le Bourhis X . Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. Glycoconj J. 2003; 18(11-12):883-93. DOI: 10.1023/a:1022200525695. View

16.

Yang G, Tan Z, Lu W, Guo J, Yu H, Yu J . Quantitative glycome analysis of N-glycan patterns in bladder cancer vs normal bladder cells using an integrated strategy. J Proteome Res. 2014; 14(2):639-53. DOI: 10.1021/pr5006026. View

17.

Julien S, Adriaenssens E, Ottenberg K, Furlan A, Courtand G, Vercoutter-Edouart A . ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology. 2005; 16(1):54-64. DOI: 10.1093/glycob/cwj033. View

18.

Chen F, Crist S, Zhang G, Iwamoto Y, See W . Interleukin-6 production by human bladder tumor cell lines is up-regulated by bacillus Calmette-Guérin through nuclear factor-kappaB and Ap-1 via an immediate early pathway. J Urol. 2002; 168(2):786-97. View

19.

Shah G, Zielonka J, Chen F, Zhang G, Cao Y, Kalyanaraman B . H2O2 generation by bacillus Calmette-Guérin induces the cellular oxidative stress response required for bacillus Calmette-Guérin direct effects on urothelial carcinoma biology. J Urol. 2014; 192(4):1238-48. PMC: 5798233. DOI: 10.1016/j.juro.2014.05.115. View

20.

Pinho S, Reis C . Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015; 15(9):540-55. DOI: 10.1038/nrc3982. View